Limits...
Efficacy and safety of solifenacin plus tamsulosin oral controlled absorption system in men with lower urinary tract symptoms: a meta-analysis.

Li MC, Wang ZY, Yang J, Guo XL, Wang T, Wang SG, Liu JH, Ye ZQ - Asian J. Androl. (2015 Jan-Feb)

Bottom Line: Solifenacin 6 mg plus TOCAS significantly improved total IPSS, storage and voiding symptoms compared with placebo.Solifenacin 6 mg plus TOCAS also improved storage symptoms compared with TOCAS alone.There was no additional benefit of solifenacin 9 mg compared with 6 mg when used in combination with TOCAS.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

ABSTRACT
We performed a meta-analysis to compare treatment with a combination of solifenacin plus tamsulosin oral controlled absorption system (TOCAS) with placebo or TOCAS monotherapy. The aim of the meta-analysis was to clarify the efficacy and safety of the combination treatments method for lower urinary tract symptoms (LUTS). We searched for trials of men with LUTS that were randomized to combination treatment compared with TOCAS monotherapy or placebo. We pooled data from three placebo-controlled trials meeting inclusion criteria. Primary outcomes of interest included changes in International Prostate Symptom Score (IPSS) and urinary frequency. We also assessed postvoid residual, maximum urinary flow rate, incidence of urinary retention (UR), adverse events. Data were pooled using random or fixed effect models for continuous outcomes and the Mantel-Haenszel method to generate risk ratio. Reductions in IPSS storage subscore and total urgency and frequency score (TUFS) were observed with solifenacin 6 mg plus TOCAS compared with placebo (P< 0.0001 and P< 0.0001, respectively). Reductions in IPSS storage subscore and TUFS were observed with solifenacin 9 mg plus TOCAS compared with placebo (P = 0.003 and P= 0.0006, respectively). Reductions in TUFS was observed with solifenacin 6 mg plus TOCAS compared with TOCAS (P = 0.01). Both combination treatments were well tolerated, with low incidence of UR. Solifenacin 6 mg plus TOCAS significantly improved total IPSS, storage and voiding symptoms compared with placebo. Solifenacin 6 mg plus TOCAS also improved storage symptoms compared with TOCAS alone. There was no additional benefit of solifenacin 9 mg compared with 6 mg when used in combination with TOCAS.

No MeSH data available.


Related in: MedlinePlus

Pooled data analysis of total International Prostate Symptom Score.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4291856&req=5

Figure 2: Pooled data analysis of total International Prostate Symptom Score.

Mentions: International Prostate Symptom Score storage subscore was investigated in all trials.789 For total IPSS, significant improvement from baseline to end of treatment compared with placebo was achieved with solifenacin 6 mg plus TOCAS (−1.50 [−2.30, −0.70], P = 0.0002, Figure 2). There was no significant improvement from baseline to end of treatment compared with placebo was achieved with solifenacin 9 mg plus TOCAS (−0.72 [−1.55, 0.12], P = 0.09). There was no significant improvement from baseline to end of treatment compared with TOCAS was achieved with solifenacin 6 mg plus TOCAS (−0.39 [−1.20, 0.41], P = 0.34) and solifenacin 9 mg plus TOCAS (0.39 [−0.99, 1.76], P = 0.58). Solifenacin 6 mg plus TOCAS significant improved total IPSS when compared with solifenacin 9 mg plus TOCAS (−0.84 [−1.60, −0.09], P = 0.03, Figure 2).


Efficacy and safety of solifenacin plus tamsulosin oral controlled absorption system in men with lower urinary tract symptoms: a meta-analysis.

Li MC, Wang ZY, Yang J, Guo XL, Wang T, Wang SG, Liu JH, Ye ZQ - Asian J. Androl. (2015 Jan-Feb)

Pooled data analysis of total International Prostate Symptom Score.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4291856&req=5

Figure 2: Pooled data analysis of total International Prostate Symptom Score.
Mentions: International Prostate Symptom Score storage subscore was investigated in all trials.789 For total IPSS, significant improvement from baseline to end of treatment compared with placebo was achieved with solifenacin 6 mg plus TOCAS (−1.50 [−2.30, −0.70], P = 0.0002, Figure 2). There was no significant improvement from baseline to end of treatment compared with placebo was achieved with solifenacin 9 mg plus TOCAS (−0.72 [−1.55, 0.12], P = 0.09). There was no significant improvement from baseline to end of treatment compared with TOCAS was achieved with solifenacin 6 mg plus TOCAS (−0.39 [−1.20, 0.41], P = 0.34) and solifenacin 9 mg plus TOCAS (0.39 [−0.99, 1.76], P = 0.58). Solifenacin 6 mg plus TOCAS significant improved total IPSS when compared with solifenacin 9 mg plus TOCAS (−0.84 [−1.60, −0.09], P = 0.03, Figure 2).

Bottom Line: Solifenacin 6 mg plus TOCAS significantly improved total IPSS, storage and voiding symptoms compared with placebo.Solifenacin 6 mg plus TOCAS also improved storage symptoms compared with TOCAS alone.There was no additional benefit of solifenacin 9 mg compared with 6 mg when used in combination with TOCAS.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

ABSTRACT
We performed a meta-analysis to compare treatment with a combination of solifenacin plus tamsulosin oral controlled absorption system (TOCAS) with placebo or TOCAS monotherapy. The aim of the meta-analysis was to clarify the efficacy and safety of the combination treatments method for lower urinary tract symptoms (LUTS). We searched for trials of men with LUTS that were randomized to combination treatment compared with TOCAS monotherapy or placebo. We pooled data from three placebo-controlled trials meeting inclusion criteria. Primary outcomes of interest included changes in International Prostate Symptom Score (IPSS) and urinary frequency. We also assessed postvoid residual, maximum urinary flow rate, incidence of urinary retention (UR), adverse events. Data were pooled using random or fixed effect models for continuous outcomes and the Mantel-Haenszel method to generate risk ratio. Reductions in IPSS storage subscore and total urgency and frequency score (TUFS) were observed with solifenacin 6 mg plus TOCAS compared with placebo (P< 0.0001 and P< 0.0001, respectively). Reductions in IPSS storage subscore and TUFS were observed with solifenacin 9 mg plus TOCAS compared with placebo (P = 0.003 and P= 0.0006, respectively). Reductions in TUFS was observed with solifenacin 6 mg plus TOCAS compared with TOCAS (P = 0.01). Both combination treatments were well tolerated, with low incidence of UR. Solifenacin 6 mg plus TOCAS significantly improved total IPSS, storage and voiding symptoms compared with placebo. Solifenacin 6 mg plus TOCAS also improved storage symptoms compared with TOCAS alone. There was no additional benefit of solifenacin 9 mg compared with 6 mg when used in combination with TOCAS.

No MeSH data available.


Related in: MedlinePlus